Randomized controlled double blind study of parallel groups to evaluate the comparative effects of low-dose of atorvastatin on proteinuria in patients with stage 3 or 4 chronic kidney disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
23
Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
Hôtel-Dieu de Québec Hospital
Québec, Quebec, Canada
proteinuria
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.